Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.

The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.

Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.

Liulishuo has listed on the New York Stock Exchange following a $71.9m initial public offering that provided an exit to publishing house Hearst.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.